Boston Scientific Corporation (NYSE:BSX) SVP Maulik Nanavaty sold 15,568 shares of the company’s stock in a transaction on Friday, February 9th. The stock was sold at an average price of $25.38, for a total value of $395,115.84. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
Boston Scientific Corporation (NYSE BSX) traded up $0.26 on Monday, reaching $26.18. The company’s stock had a trading volume of 8,449,845 shares, compared to its average volume of 10,008,726. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.50 and a current ratio of 0.72. The stock has a market capitalization of $35,590.00, a P/E ratio of 374.00, a price-to-earnings-growth ratio of 1.88 and a beta of 0.81. Boston Scientific Corporation has a one year low of $23.29 and a one year high of $29.93.
Boston Scientific (NYSE:BSX) last posted its earnings results on Thursday, February 1st. The medical equipment provider reported $0.34 EPS for the quarter, hitting the Zacks’ consensus estimate of $0.34. The company had revenue of $2.41 billion for the quarter, compared to the consensus estimate of $2.39 billion. Boston Scientific had a return on equity of 24.04% and a net margin of 1.15%. Boston Scientific’s quarterly revenue was up 9.9% compared to the same quarter last year. During the same period in the previous year, the business earned $0.30 earnings per share. equities analysts anticipate that Boston Scientific Corporation will post 1.37 EPS for the current fiscal year.
A number of brokerages recently weighed in on BSX. Canaccord Genuity began coverage on Boston Scientific in a report on Tuesday, October 24th. They set a “buy” rating and a $36.00 price objective on the stock. Zacks Investment Research raised Boston Scientific from a “sell” rating to a “buy” rating and set a $33.00 price objective on the stock in a report on Friday, October 20th. BMO Capital Markets upped their price objective on Boston Scientific from $30.00 to $32.00 and gave the stock an “outperform” rating in a report on Friday, October 27th. SunTrust Banks set a $34.00 price objective on Boston Scientific and gave the stock a “buy” rating in a report on Tuesday, October 31st. Finally, Barclays reaffirmed a “buy” rating and set a $32.00 price objective on shares of Boston Scientific in a report on Wednesday, January 10th. One analyst has rated the stock with a sell rating, five have given a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $31.00.
About Boston Scientific
Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.